175 related articles for article (PubMed ID: 38569025)
21. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic miR-106b-5p promotes cisplatin resistance in triple-negative breast cancer by targeting GDF11.
Zhou Q; Hu Q
Histol Histopathol; 2024 Apr; 39(4):533-541. PubMed ID: 37905957
[TBL] [Abstract][Full Text] [Related]
23. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
24. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis.
Chen F; Wang Q; Yu X; Yang N; Wang Y; Zeng Y; Zheng Z; Zhou F; Zhou Y
Cell Death Dis; 2021 Apr; 12(4):370. PubMed ID: 33824311
[TBL] [Abstract][Full Text] [Related]
25. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
27. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
[TBL] [Abstract][Full Text] [Related]
28. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.
Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J
J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418
[TBL] [Abstract][Full Text] [Related]
29. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
30. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
31. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.
He Y; Xiao B; Lei T; Xuan J; Zhu Y; Kuang Z; Liu J; He J; Li L; Sun Z
Gene; 2023 Apr; 860():147227. PubMed ID: 36709879
[TBL] [Abstract][Full Text] [Related]
32. A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer.
Song R; Guo P; Ren X; Zhou L; Li P; Rahman NA; Wołczyński S; Li X; Zhang Y; Liu M; Liu J; Li X
Mol Cancer; 2023 Jul; 22(1):104. PubMed ID: 37408008
[TBL] [Abstract][Full Text] [Related]
33. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
34. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract][Full Text] [Related]
35. GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway.
Li C; Geng C
Biol Pharm Bull; 2023; 46(2):209-218. PubMed ID: 36724950
[TBL] [Abstract][Full Text] [Related]
36. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
37. Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells.
Chen L; Zhang J; Lyu Z; Chen Y; Ji X; Cao H; Jin M; Zhu J; Yang J; Ling R; Xing J; Ren T; Lyu Y
Cell Death Dis; 2018 Oct; 9(11):1050. PubMed ID: 30323195
[TBL] [Abstract][Full Text] [Related]
38. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
39. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
[TBL] [Abstract][Full Text] [Related]
40. ZNF33A Promotes Tumor Progression and BET Inhibitor Resistance in Triple-Negative Breast Cancer.
Wang X; Wei X; Cao Y; Xing P
Am J Pathol; 2022 Oct; 192(10):1458-1469. PubMed ID: 35843263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
